Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - hydrochlorothiazide 12.5mg; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water   quinoline yellow starch titanium dioxide - for the treatment of hypertension, for patients in whom combination therapy is appropriate

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bisacodyl 5mg - enteric coated tablet - 5 mg - active: bisacodyl 5mg excipient: calcium carbonate colloidal silicon dioxide gelatin lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone   purified talc   quinoline yellow silicon sodium starch glycolate starch sucrose

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diltiazem hydrochloride 60mg - film coated tablet - 60 mg - active: diltiazem hydrochloride 60mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate methyl hydroxybenzoate microcrystalline cellulose opadry quinoline yellow sunset yellow fcf - patients with moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - warfarin sodium 1mg - tablet - 1 mg - active: warfarin sodium 1mg excipient: amaranth lactose magnesium stearate maize starch quinoline yellow stearic acid - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, thromboembolism associated with atrial fibrillation, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - warfarin sodium 5mg - tablet - 5 mg - active: warfarin sodium 5mg excipient: brilliant blue fcf lactose magnesium stearate maize starch quinoline yellow stearic acid - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, thromboembolism associated with atrial fibrillation, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - loperamide hydrochloride 2mg - capsule - 2 mg - active: loperamide hydrochloride 2mg excipient: erythrosine gelatin   indigo carmine   iron oxide black lactose monohydrate magnesium stearate maize starch opacode quinoline yellow titanium dioxide   - diamide is indicated for the symptomatic control of acute and chronic diarrhoea. in patients with an ileostomy it can be used to reduce the number and volume of stools and to harden their consistency.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - bromhexine hydrochloride 0.8 mg/ml; pholcodine 1 mg/ml;  ;  ;   - oral solution - 0.8mg/1mg per ml - active: bromhexine hydrochloride 0.8 mg/ml pholcodine 1 mg/ml       excipient: citric acid glycerol grenadine flavour 053040 hyetellose methyl hydroxybenzoate patent blue v propyl hydroxybenzoate purified water quinoline yellow saccharin sodium sorbitol

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b opaglos white 6000 povidone purified water quinoline yellow sucrose lactose monohydrate magnesium stearate microcrystalline cellulose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hydrochlorothiazide 12.5mg;  ;  ; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg     losartan potassium 50mg   excipient: carnauba wax hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose quinoline yellow starch titanium dioxide - hypertension hyzaar is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy hyzaar is a combination of losartan (cozaar) and hydrochlorothiazide. in patients with hypertension and left ventricular hypertrophy, losartan, often in combination with hydrochlorothiazide, reduces the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - carbidopa monohydrate 26.9mg equivalent to carbidopa 25 mg (contains approx. 7% moisture); levodopa 100mg - tablet - 100mg/25mg - active: carbidopa monohydrate 26.9mg equivalent to carbidopa 25 mg (contains approx. 7% moisture) levodopa 100mg excipient: magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate starch - kinson is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. kinson frequently is helpful in the management of tremor, dysphagia, sialorrhea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of kinson usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, kinson permits more patients to obtain adequate relief of the symptoms of parkinson's disease. kinson is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).